PatientsVille.com Logo


Rifaximin Medical Research Studies

Up-to-date List of Rifaximin Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Rifaximin Medical Research Studies

Rank Status Study
1 Recruiting Rifaximin to Prevent Recurrent HCV-Related Fibrosis After Liver Transplant
Conditions: Hepatitis C Virus;   Liver Transplant Recipient;   Recurrent Fibrosis
Interventions: Drug: Rifaximin;   Drug: Placebo
Outcome Measures: Significant recurrence of Hepatitis C;   Serum LPS measurements;   Measurement of mRNA markers of the fibrosis cascade;   Number of adverse events and severe adverse events
2 Unknown  Induction of Clinical Response Using Rifaximin in Crohn's Disease
Condition: Crohn's Disease
Interventions: Drug: Placebo Comparator;   Drug: Rifaximin
Outcome Measures: Evaluate the efficacy of Rifaximin 550 mg bid compared to placebo in achieving clinical response in moderate to severe Crohn's Disease (CD) subjects as determined by a > 100 point decrease in the Crohn's Disease Activity Index (CDAI);   Evaluate the efficacy of Rifaximin compared to placebo at inducing clinical remission in CD subjects;   Evaluate the safety profile of Rifaximin in subjects with active CD;   Evaluate the effect Rifaximin has on the quality of life in subjects with CD compared to placebo;   Evaluate if there are any clinical parameters which might predict response to Rifaximin;   Compare mean changes in CDAI scores between Rifaximin and placebo treated subjects
3 Recruiting Impact of an Antibiotic (Rifaximin) on Liver Scarring in HIV-Infected Patients With Liver Disease
Conditions: HIV;   Hepatitis C
Intervention: Drug: Rifaximin
Outcome Measures: Liver fibrosis progression as measured by transient elastography;   Levels of sCD14 in HIV-infected patients with liver disease taking Rifaximin;   Safety of prolonged use of Rifaximin in HIV patients taking many other medications
4 Recruiting The Safety/Efficacy Of Rifaximin With/Without Lactulose In Subjects With A History Of Recurrent Hepatic Encephalopathy
Conditions: Hepatic Encephalopathy;   Cirrhosis
Interventions: Drug: Rifaximin;   Drug: Rifaximin and Lactulose
Outcome Measures: Time to first breakthrough HE episode;   Time to first HE-related hospitalization;   All Cause Mortality
5 Recruiting Rifaximin and Propranolol Combination Therapy Versus Propranolol Monotherapy in Cirrhotic Patients
Conditions: Liver Cirrhosis;   Portal Hypertension
Interventions: Drug: Rifaximin + propranolol;   Drug: Propranolol + Placebo
Outcome Measures: Hepatic vein pressure gradient(HVPG);   occurence of gastrointestinal bleeding
6 Recruiting Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis
Condition: Liver Cirrhosis
Interventions: Drug: Placebo;   Drug: Rifaximin SSD 40 mg IR tablet;   Drug: Rifaximin SSD 80 mg IR tablet;   Drug: Rifaximin SSD 40 mg SER tablet;   Drug: Rifaximin SSD 80 mg SER tablet;   Drug: Rifaximin SSD 80 mg IR tablet + Rifaximin SSD 80 mg SER tablet
Outcome Measures: Time to all-cause mortality or hospitalization that is attributable to complications of liver disease.;   Overall hospitalization rate due to each complication of liver disease or all-cause mortality over the 24-week treatment period.;   Pharmacokinetics of Rifaximin and its metabolite.;   Incidence of treatment-emergent adverse events.;   Change in clinical laboratory parameters.;   Changes in electrocardiogram measurements;   Changes in indices of health outcomes
7 Recruiting Rifaximin for Preventing Relapse of Clostridium Associated Diarrhoea
Condition: Clostridium Difficile Infection
Interventions: Drug: Rifaximin;   Drug: Placebo
Outcome Measures: Difference in % relapse between Rifaximin and placebo at 12 weeks;   Proportion relapsed, re-hospitalisation and bowel symptoms
8 Recruiting Rifaximin Predicts the Complications of Decompensated Cirrhosis
Condition: Cirrhosis
Intervention: Drug: Rifaximin
Outcome Measures: Serum endotoxin level;   Hydrogen breath test;   Fecal flora;   Liver biochemistry tests;   Numbers of complications of cirrhosis;   Serum levels of inflammatory factors
9 Recruiting The Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy
Condition: Hepatic Encephalopathy
Interventions: Drug: Placebo;   Drug: Rifaximin
Outcome Measures: Time to first Hepatic Encephalopathy(HE) breakthrough episode;   Time to first HE-related hospitalization;   All Cause Mortality
10 Not yet recruiting Pilot Study Of The Effect Of Rifaximin On B-Cell Dysregulation In Cirrhosis
Conditions: Liver Cirrhosis;   Chronic Hepatitis C
Interventions: Drug: Rifaximin;   Drug: Placebo
Outcome Measures: Change in CD27+ B-cell frequency;   Change in basal B-cell activation
11 Not yet recruiting Randomised Controlled Trial of Mechanistic Effects of Rifaximin in Cirrhosis and Chronic Hepatic Encephalopathy
Conditions: Liver Cirrhosis;   Hepatic Encephalopathy.
Intervention: Drug: Rifaximin
Outcome Measures: Rifaximin-α reducing neutrophil spontaneous oxidative burst ex vivo;   Neutrophil bacteriocidal capacity;   Reduction in systemic inflammation;   Improvement in neutrophil phenotype and function;   Alterations in faecal microbiota at 90 days;   Reduction in intestinal permeability and changes in faecal biomarkers (calprotectin) at 90 days.;   Changes in urinary and plasma metabonomic profile
12 Recruiting Rifaximin for Chronic Immune Activation in People With HIV
Conditions: HIV;   Rifaximin
Interventions: Drug: Rifaximin;   Drug: Placebo
Outcome Measure: The primary objective is to compare changes in sCD14 levels during the Rifaximin phase of the study and compare it with the changes in sCD14 levels during the placebo phase
13 Recruiting Intestinal Decontamination With Rifaximin. The Inflammatory and Circulatory State in Patients With Cirrhosis
Conditions: Liver Cirrhosis;   Ascites
Interventions: Drug: Rifaximin;   Drug: placebo
Outcome Measures: Change from baseline in Hepatic venous pressure gradient (HVPG);   Change from baseline in Glomerular filtration rate (GFR)
14 Recruiting The Rifaximin Study in CVID
Condition: Common Variable Immunodeficiency (CVID)
Intervention: Drug: Rifaximin
Outcome Measure: Changes in inflammatory and anti-inflammatory mediators
15 Not yet recruiting Rifaximin for the Secondary Prevention of Spontaneous Bacterial Peritonitis Recurrence in Cirrhotic Patients
Condition: Spontaneous Bacterial Peritonitis
Interventions: Drug: Rifaximin;   Drug: Ciprofloxacin
Outcome Measures: The recurrence rate of spontaneous bacterial peritonitis;   mortality;   The recurrence of culture-negative spontaneous bacterial peritonitis;   Causative bacteria of recurrent spontaneous bacterial peritonitis;   Change of gut microbiota;   Infections other than spontaneous bacterial peritonitis
16 Recruiting Effects of Rifaximin in Patients With Acute Alcoholic Hepatitis
Condition: Alcoholic Hepatitis
Interventions: Drug: Prednisone;   Drug: Rifaximin
Outcome Measures: Rate of bacterial infections;   Rate of Decompensations of Liver Cirrhosis
17 Recruiting Rifaximin for Functional Dyspepsia
Condition: Functional Dyspepsia
Interventions: Drug: Rifaximin;   Drug: Placebo
Outcome Measures: Adequate relief of dyspeptic symptoms at end of treatment;   Individual dyspeptic symptom scores
18 Unknown  RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial
Condition: Hepatic Encephalopathy
Intervention: Drug: Rifaximin alone, Rifaximin combined with Lactulose
Outcome Measures: Number of hospitalizations for HE;   Changes in psychometric testing during study period;   Number of hospitalization days for all causes;   Death or survival to liver transplantation;   Rate of adverse events with Rifaximin treatment
19 Recruiting Double Blind Randomized Study, Comparing Rifaximin vs Placebo for the Prevention of Encephalopathy in Patients Treated by TIPS
Condition: Cirrhosis
Interventions: Drug: Rifaximin;   Drug: placebo
Outcome Measures: first episode of covert encephalopathy in patients treated by TIPS;   number of hospitalisation days;   Frequency of kidney insufficiency;   transplants, deaths;   intestinal microbiota
20 Recruiting Comparative Study of Rifaximin Versus Norfloxacin in the Secondary Prophylaxis of Spontaneous Bacterial Peritonitis
Conditions: Spontaneous Bacterial Peritonitis;   Ascites;   Liver Cirrhosis
Interventions: Drug: Rifaximin;   Drug: Norfloxacin
Outcome Measure: Number of participants with recurrence of SBP

These studies may lead to new treatments and are adding insight into Rifaximin etiology and treatment.

A major focus of Rifaximin research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Rifaximin